Analogic (NASDAQ:ALOG) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold primarily to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Automatic Explosives Detection, Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, and Advanced Signal Processing. For over 40 years Analogic has created markets by anticipating and solving some of the world’s most complex medical and engineering challenges. Many of the largest, best-known medical imaging companies incorporate our high-performance imaging subsystems into their products. These products are used in most major healthcare facilities around the world to detect and treat disease. They provide extensive design, development, manufacturing, and test capabilities, and offer a unique combination of clinical knowledge and product design experience. “

A number of other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Analogic from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 6th. Jefferies Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Analogic in a research report on Friday, December 8th.

Shares of Analogic (NASDAQ ALOG) opened at $85.65 on Wednesday. The stock has a market cap of $1,034.98 and a PE ratio of -14.97. Analogic has a 12 month low of $66.00 and a 12 month high of $89.50.

Analogic (NASDAQ:ALOG) last issued its earnings results on Wednesday, December 6th. The medical research company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.32. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $100.55 million. Analogic had a negative net margin of 15.06% and a positive return on equity of 5.09%. The company’s revenue for the quarter was down 11.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.43 EPS. research analysts forecast that Analogic will post 2.86 earnings per share for the current year.

Several large investors have recently made changes to their positions in the stock. Cigna Investments Inc. New bought a new stake in shares of Analogic during the 4th quarter valued at about $483,000. First Quadrant L P CA grew its position in shares of Analogic by 54.5% during the 4th quarter. First Quadrant L P CA now owns 14,991 shares of the medical research company’s stock valued at $1,255,000 after buying an additional 5,291 shares during the last quarter. Strs Ohio grew its position in shares of Analogic by 24.1% during the 4th quarter. Strs Ohio now owns 10,800 shares of the medical research company’s stock valued at $904,000 after buying an additional 2,100 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Analogic during the 4th quarter valued at about $3,102,000. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Analogic by 12.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 131,437 shares of the medical research company’s stock valued at $11,008,000 after buying an additional 14,282 shares during the last quarter. 98.22% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Downgrades Analogic (ALOG) to Hold” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/zacks-investment-research-downgrades-analogic-alog-to-hold/1838794.html.

Analogic Company Profile

Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.

Get a free copy of the Zacks research report on Analogic (ALOG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Analogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Analogic and related companies with MarketBeat.com's FREE daily email newsletter.